Compare TG Therapeutics Inc (TGTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Union Pacific Corporation — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Union Pacific Corporation trades at $278.34 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 20.3× TG Therapeutics Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Union Pacific Corporation for 105 Days on average.
| TGTX | UNP | |
|---|---|---|
Market Cap | $8.16B | $165.27B |
Volume | 1,735,121 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $59.06 | $310.62 |
52-Week Low | $26.94 | $216.37 |
Typical Hold Time | 16 Days | 105 Days |
Enterprise Value | $8.37B | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Union Pacific (UNP) trades at $278.34, up 1.33% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 28.85% net margins and consistent earnings beats, while maintaining positive cash flow generation. Recent developments include deployment of battery-electric locomotives and progress on the Norfolk Southern combination, positioning the railroad for future growth.
The outlook remains positive with analyst consensus pointing to 19% upside potential to the $332.10 price target. Key opportunities include pricing power from high diesel costs shifting freight to rail, while risks center on merger uncertainty and fuel cost pressures on operating ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
